NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER
申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP3251679A1
公开(公告)日:2017-12-06
Use of a compound of formula (IA):
wherein RA is a halogen atom, a lower alkyl group or a lower alkoxy group; RB is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a mono- or di-lower alkylamino group; and Rc is hydrogen atom; or RB and RC taken together are a fused benzene ring which may be substituted by a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group or a halo-lower alkoxy group;
in the manufacture of a medicament for the treatment of diabetes mellitus (type 1 and type 2), diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, postprandial hyperglycemia, or delayed wound healing.
使用式(IA)化合物:
其中 RA 是卤素原子、低级烷基或低级烷氧基;RB 是任选被卤素原子、氰基、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基或单或双低级烷基氨基取代的苯基;或可被卤素原子、氰基、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基或单低或双低烷基氨基取代的杂环基团;且 Rc 为氢原子;或 RB 和 RC 合在一起为可被卤素原子、低级烷基、卤代低级烷基、低级烷氧基或卤代低级烷氧基取代的融合苯环;
用于制造治疗糖尿病(1 型和 2 型)、糖尿病视网膜病变、糖尿病神经病 变、糖尿病肾病、餐后高血糖或伤口延迟愈合的药物。